Elekta Ab Class B · OMXSTO:EKTA_B
Elekta Ab Class B — Investor Day (September 2013)
60 slides from Elekta Ab Class B's investor day presentation, Sep 23, 2013
Slide 1: Elekta Capital Markets Day
Elekta Capital Markets Day 23 September 2013, Atlanta 1
Slide 2: Important information
Important information This presentation includes forward-looking statements including, but not limited to, statements relating to operational and financial performance, market conditions, and other similar matters. These forward-looking statements are based on current expectations about future event
Slide 3: Elekta Capital Markets Day agenda
Elekta Capital Markets Day 09:00 Innovation ● Growth Tomas Puusepp, President and CEO 09.15 Radiation Oncology Professor Frederik Wenz Dee Mathieson, Senior Vice President 09.45 Elekta Oncology Kevin Brown, Global Vice President Scientific Research 10.00 Elekta Software Todd Powell, Executive Vice P
Slide 4: Welcome to Elekta
Welcome to Elekta ASTRO - Capital Markets Day 2013 Tomas Puusepp President and CEO 4
Slide 5: Elekta is stronger than ever
Elekta is stronger than ever • Leading in emerging markets • Number one in Europe and Asia Pacific • Superior technology with Versa HD™ • Increased investments in R&D • MRI-guided radiation therapy from concept to prototype* *Research project, not a product for sale. 5
Slide 6: 21 million new cancer cases per year by 2030
21 million new cancer cases per year by 2030 Number of new cancer cases Increasing population living Millions with cancer 25 • Improved treatments Total - cancer becomes more 20 of a chronic disease 15 • Re-treatments Men 10 Women 5 0 2010 2015E 2020E 2025E 2030E WHO forecast of new cancer excluding
Slide 7: >50% of cancer patients to receive radiation therapy in established markets
>50% of cancer patients to receive radiation therapy in established markets Share of cancer patients receiving radiation therapy today • Increased efficiency USA 63% • Upgrades of installed base Europe 30-50% • Addition of new capacity Canada 32% • New body sites Japan 25-30% 7
Slide 8: Market drivers
Market drivers Extended Emerging solutions markets Evidence- Efficiency based medicine 8
Slide 9: Increased investments in product development
Increased investments in product development Growth in R&D of >20% this year to ~10% of net sales • Groundbreaking MR linac research program* • Drive SRS market with Leksell Gamma Knife® • Software – capture full potential with new solutions • Brachytherapy – develop new body sites • Leadership with
Slide 10: New solutions at ASTRO
New solutions at ASTRO Esteya® Versa HD™ Monaco® 5.0 XVI 5.0 10
Slide 11: Elekta Learning and Innovation Center
Grand opening of Elekta Learning and Innovation Center • Role model for Elekta’s global education and training program 11
Slide 12: Market outlook unchanged
Market outlook unchanged North and South America • Still uncertainty regarding US health care reform and reimbursement • Tender for 80 linear accelerators ongoing in Brazil Europe, Middle East and Africa • Good growth in Northern and Central Europe • High demand in emerging markets Asia Pacific • Go
Slide 13: Radiation Oncology
Radiation Oncology Frederik Wenz MD, Professor and Chairman Department of Radiation Oncology University Medical Center Mannheim University of Heidelberg 13
Slide 14: Elekta Oncology
Elekta Oncology Versa HD™ Dee Mathieson Senior Vice President Oncology Business Line Management 14
Slide 15: Exceeding expectations
Exceeding expectations Versa HD™ shipped to 13 countries 15
Slide 16: Versatility
Versatility Conventional Advanced stereotactic Versa HD™ radiotherapy precision One solution. Unlimited possibilities. 16
Slide 17: Superior target conformance
Superior target conformance • Fully integrated with Elekta´s Agility™ MLC • 160 x 5 mm leaves across the full 40 cm x 40 cm field • Efficiently cover multiple targets with interdigitation and island shapes • Fast leaf speed Image courtesy of Christopher Walker, Head of Radiotherapy Physics The James
Slide 18: Clinical versatility
Clinical versatility High Multiple stereotactic targets SBRT e.g. Lung Dose per fraction Simple conformal ! e.g. Breast 3 cm/s Longer fields e.g. H&N VMAT Standard Simple Plan Complex 18
Slide 19: Clinical versatility
Clinical versatility High Multiple stereotactic targets SBRT High dose rates e.g. Lung Dose per fraction Simple conformal ! e.g. Breast MLC shaping capability 3 cm/s Longer fields e.g. H&N VMAT Standard Simple Plan Complex 19
Slide 20: Dedicated to personalized patient solutions
Dedicated to personalized patient solutions • Brain & Spine • Head & Neck • Lung • Breast • Prostate Addressing the specific anatomical challenges of radiotherapy Enhancing the Versa HD™ core solution 20
Slide 21: New at ASTRO - XVI 5.0
New at ASTRO - XVI 5.0 (*) ELEKTA
Slide 22: XVI 5.0 benefits
Faster MLC leaf speed Higher dose rate Larger high-definition • Greater versatility field size • Improved efficiency • Higher quality patient care 22
Slide 23: Elekta Oncology: MR linac
Elekta Oncology MR linac Kevin Brown Global Vice President Scientific Research 23
Slide 24: Pioneering the next major breakthrough
Pioneering the next major breakthrough State of the art MR imaging, state of the art radiation therapy • Building on a decade of research from UMC, Utrecht, NL – In collaboration with Elekta and Philips • Research demonstrated unparalleled soft tissue visualization during irradiation • Research coll
Slide 25: Elekta and Philips press release on MRI-guided radiation therapy consortium
PS (*) ELEKTA PHILI Press information October 25, 2012 Adds iation Therapy rtium on MRI-Guided Radiati ch Conso ps Resear ital ; ni van Leeuwenhoek Hosp Elekta and Phili ony tion ° jotherapy innova Institute- ing next-generation radiotherap ho Netherlands a nelaatad to developing ~ “YSE: ter as Coll
Slide 26: Research into MRI-guided radiation therapy
Research into MRI-guided radiation therapy • MRI magnet full on at 1.5T and able to image • Linac able to radiate • MLC able to move leaves • Gantry able to rotate All at the same time 26
Slide 27: Developing a Global Research Consortium
Developing a Global Research Consortium The MR Linac Consortium aims to: • Demonstrate improved patient benefits • Extend radiation therapy with new treatment techniques and be able to treat more indications Each consortium member will have a pilot MR linac for: • Identifying clinical benefits and t
Slide 28: Elekta Software
Elekta Software Todd Powell Executive Vice President 28
Slide 29: World leader in cancer care software solutions
World leader in cancer care software solutions 15,000 users are supported by over 400 dedicated experts driving best in class development Over 1,000 parameters are managed during a typical treatment 29
Slide 30: Elekta's product portfolio integrated in MOSAIQ
Elekta’s product portfolio integrated in MOSAIQ® Elekta treatment Versa HD™ planning portfolio MOSAIQ® Elekta Compact™ Leksell Gamma Knife® Brachytherapy Agility™ solutions 30
Slide 31: One platform – multiple locations
One platform – multiple locations MOSAIQ® 100 sites Clusters of 4 to 5 sites each Transitioning to a cloud- based approach 9 sites One MOSAIQ database 4 sites One MOSAIQ database 31
Slide 32: Elekta software in the future
Elekta software in the future • Personalized care represents the future of optimized cancer care • Open systems are our legacy and our future • Physician’s intent can drive automated workflows and point of care decision support • Human-centered design can transform our lives and the lives of our pat
Slide 33: Treatment planning roadmap
Treatment planning roadmap – unified, consolidated, powerful Focal 4D Monaco FocalPro ABAS ERGO++ Installed Product XiO FocalSim Oncentra Available Now!! MOSAIQ RTP Evaluate Monaco 5* Fiscal MOSAIQ RTP Evaluate Locate Delineate Simulate Calculate 2014/15 *Pending 510k approval
Slide 34: New at ASTRO - Monaco 5.0
New at ASTRO - Monaco® 5.0 • Converges the best capabilities of TPS portfolio in a single, versatile platform • Full range of treatment techniques: VMAT, IMRT, 3D and SRS/SRT • Improves simplicity and productivity with redesigned workflows and user interface • New multi-threaded CPU and GPU-based ar
Slide 35: Elekta Capital Markets Day
Elekta Capital Markets Day 23 September 2013, Atlanta 35
Slide 36: Elekta Capital Markets Day agenda
Elekta Capital Markets Day 09:00 Innovation ● Growth Tomas Puusepp, President and CEO 09.15 Radiation Oncology Professor Frederik Wenz Dee Mathieson, Senior Vice President 09.45 Elekta Oncology Kevin Brown, Global Vice President Scientific Research 10.00 Elekta Software Todd Powell, Executive Vice P
Slide 37: Elekta Neuroscience
Elekta Neuroscience Åsa Hedin Executive Vice President 37
Slide 38: >800,000 patients treated with Gamma Knife Radiosurgery
>800,000 patients treated with Gamma Knifer® Radiosurgery Ocular disorders <1% Functional targets 7% Malignant tumors Vascular disorders 12% 44% Benign tumors 36% Source: Leksell Gamma Knife Society (preliminary statistics for 2011; not all sites reporting) 38
Slide 39: Unmatched precision, efficiency and clinical outcome
Unmatched precision, efficiency and clinical outcome Precision Clinical evidence Efficacy Safety
Slide 40: Importance of clinical data management
Importance of clinical data management Leksell Gamma Knife® Leksell Gamma Knife® Society Registry Site Registry Leksell Gamma Knife Center Leksell Gamma Knife Leksell Gamma Knife® Center Leksell Gamma Knife Society Registry Society Registry Leksell Gamma Knife Center • Support research and • Benchma
Slide 41: Professor Dheerendra Prasad
Professor Dheerendra Prasad Professor of Neurosurgery and Radiation Oncology at Roswell Park Cancer Institute and serves as the Medical Director of the Radiation Medicine Department and Director of the Gamma Knife Center • Both a certified Neurosurgeon and a Radiation Oncologist • >75 papers in peer
Slide 42: Dheerendra Prasad MD MCh
Dheerendra Prasad MD MCh Director Gamma Knife Center Medical Director, Radiation Medicine Professor of Neurosurgery, Radiation Oncology & Pediatrics Roswell Park Cancer Institute Buffalo, NY
Slide 43: Elekta Brachytherapy
Elekta Brachytherapy John Lapré Executive Vice President 43
Slide 44: Shaping the future of brachytherapy
Shaping the future of brachytherapy Elekta Brachytherapy innovation themes Treatment certainty Workflow efficiency Access to brachytherapy System integration Adaptive combined Patient experience therapy 44
Slide 45: World-leading product portfolio
World-leading product portfolio Treatment Real-time prostate Electronic Treatment Applicators planning solution brachy for skin delivery New at ASTRO LumenCare™ Azure* Oncentra® New solution (Lung) ACE* Dose Complete Prostate Esteya®* Fletcher CT/MR Shielded* Calculations Flexitron ® family (Gyn) 4.
Slide 46: Setting new industry standard in treatment delivery
The new Flexitron® family Setting new industry standard in treatment delivery • New standard in treatment delivery – Tailored to needs with 10, 20, 40 channels – Efficiency through improved usability • Added Cobalt-60 as an option – Only for selected markets and not available in the US – Access wher
Slide 47: Skin cancer - rapidly increasing
Skin cancer - rapidly increasing • Incidence of skin 3.5 million new cases in US per year cancer growing Melanoma 2% at 8% per year • More than all 20% cancers together Squamous cell carcinoma 78% • Potential to (SCC) Basal cell increase radiation carcinoma (BCC) therapy’s role Source: Cancer Facts
Slide 48: Opportunity for a solution that benefits all stakeholders
Opportunity for a solution that benefits all stakeholders and creates partnership Prefer (non-invasive) Create non-threatening treatment options treatment experience Patient Ability to offer radiation Challenged by growing service by RO at the skin cancer incidence dermatology clinic Dermatology Eas
Slide 49: HDR brachytherapy made more accessible
® Benefits of HDR HDR brachytherapy brachytherapy made moremoreaccessible accessible Availability in target markets is dependent on regulatory admissions and approvals. 510(k) submitted. 49
Slide 50: First patient treated in Spain
First patient treated in Spain 50
Slide 51: Esteya
Esteya® Attractive economic profile with fast & reliable technology • Highly precise treatment system – Easy to use – Minimal room-shielding requirements – Comprehensive service program • Great opportunity to expand RO service for treating skin cancer – Controlled market rollout initiated – Reimburs
Slide 52: Elekta North America
Elekta North America Jay Hoey Executive Vice President 52
Slide 53: North America – world's largest market
North America – world’s largest market • Most advanced radiotherapy market in the world Order growth • 30% of the world’s linear accelerators CAGR 11% • Growth is driven by: – Aging population – Increasing cancer incidence – Higher survival rates – Technological advancements • Trend towards long-ter
Slide 54: Leading product portfolio
Leading product portfolio • VersaHD™ – exceeding expectations • New software solutions – Monaco® 5.0 • Brachytherapy – Esteya® rollout, new Flexitron® • Leksell Gamma Knife® – Increased reimbursement proposed • MR linac – research project* – Next major breakthrough *Research project, not a product f
Slide 55: RNA awards & industry rankings
RNA awards & industry rankings • 2013 MD Buyline – Elekta # 1 vendor in linacs, SRS, OIS, and brachy • 2013 Best in KLAS for radiation therapy • #1 Elekta Leksell Gamma Knife ® Perfexion™ (2013/2012/2011) • #2 Elekta Infinity™ • 2012 & 2011 Best in KLAS* – Elekta MOSAIQ® *2013 awards out December 20
Slide 56: Elekta Learning and Innovation Center
LINC sets the new standard Elekta Learning and Innovation Center • Ideal environment for learning • Innovative collaboration with users • Elekta’s link with users and industry 56
Slide 57: US reimbursement update
US reimbursement update Reimbursement • In general, higher reimbursement proposed for next year • Leksell Gamma Knife® - revised proposal but still improved • Final decision expected in November Medical device tax • 2.3% on the majority of hardware and software sales 57
Slide 58: Elekta North America is gaining share
Elekta North America is gaining share Market share - installed base Market share – new orders (FY12/13) (FY12/13) Accuray 5% Elekta Accuray 3% Siemens 9% 13% Elekta 25% Varian 73% Varian 72% Sources: IMV, MD Buyline, Internal Win / Loss reports, Management analysis 58
Slide 59: Continued growth expected
Continued growth expected • Underlying market growth expected to continue • Focus on comprehensive solutions and partner with customers • Growth from legacy Siemens installed base • Leverage on strong footholds within software (OIS) and brachytherapy 59
Slide 60: Human Care Makes the Future Possible
Human Care Makes the Future Possible